The recommendation makes a second drug available in England for treating transthyretin amyloidosis with cardiomyopathy.

A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.

They face a difficult choice, since the treatment may benefit their children but comes with serious risks and unknowns, particularly following reports of patient deaths.

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.